A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 420

Sponsor: Regeneron Pharmaceuticals

Summary

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times

Eligibility Criteria

Key Inclusion Criteria: 1\. Participant has elevated LDL-C level, as defined in the protocol Key Exclusion Criteria: 1. Participant plans to initiate or change dose of lipid-lowering therapy 2. Use of any PCSK9 inhibitors NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07477704). StuddyBuddy aggregates publicly available trial information.